Aytu BioPharma posts Q1 2027 revenue around $14.8 million and EPS of –$0.20, beating estimates

Aytu BioPharma reported fiscal Q1 2027 revenue of about $14.8 million, roughly 6.8‑6.9% higher year‑over‑year, and a GAAP EPS of –$0.20, which topped analyst forecasts by $0.14. The quarter ended with a net loss of $3.9 million, wider than the prior‑year profit of $2.0 million. The company remains in the process of being acquired by Rosemont, with the tender offer expected to start soon.

The earnings beat may bolster confidence in the pending Rosemont acquisition, as the company highlighted in its filing. Investors will watch the tender offer timeline for potential price impact.

  • 1Fiscal Q1 2027 revenue was $14.8 million, up 6.9% year‑over‑year.
  • 2Net loss for the quarter was $3.9 million, compared with a $2.0 million profit a year earlier.
  • 3GAAP EPS was –$0.20, beating estimates by $0.14.
  • 4Revenue was $14.84 million, up 6.8% year‑over‑year, exceeding expectations by $1.57 million.
  • 5The company is pending acquisition by Rosemont, with the tender offer commencement and completion as upcoming catalysts.

Sources